Symbols / TENX
TENX Chart
About
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 72.74M |
| Enterprise Value | 373.28M | Income | -43.33M | Sales | — |
| Book/sh | 2.39 | Cash/sh | 2.45 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -7.43 | PEG | — |
| P/S | — | P/B | 4.87 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 15.06 |
| Current Ratio | 15.58 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.74 | EPS next Y | -1.57 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 16:00 | ROA | -29.14% |
| ROE | -44.80% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 6.24M |
| Shs Float | 6.21M | Short Float | 1.96% | Short Ratio | 0.36 |
| Short Interest | — | 52W High | 18.38 | 52W Low | 4.63 |
| Beta | 1.41 | Avg Volume | 239.44K | Volume | 105.14K |
| Target Price | $22.90 | Recom | None | Prev Close | $12.10 |
| Price | $11.65 | Change | -3.72% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$22.90
Mean price target
2. Current target
$11.65
Latest analyst target
3. DCF / Fair value
$-34.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.65
Low
$13.52
High
$30.00
Mean
$22.90
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | main | Guggenheim | Buy → Buy | $25 |
| 2025-09-08 | init | Piper Sandler | — → Overweight | $20 |
| 2025-08-14 | main | Guggenheim | Buy → Buy | $14 |
| 2024-10-24 | init | Leerink Partners | — → Outperform | $16 |
| 2024-02-20 | reit | Roth MKM | Buy → Buy | $30 |
- $TENX stock is up 11% today. Here's what we see in our data. - Quiver Quantitative hu, 18 Dec 2025 08
- (TENX) and the Role of Price-Sensitive Allocations - Stock Traders Daily Fri, 20 Feb 2026 00
- Tenax Therapeutics Stock: A Speculative Buy (NASDAQ:TENX) - Seeking Alpha Fri, 09 Jan 2026 08
- Heart failure drug trials expand as Tenax starts second Phase 3 study - Stock Titan Wed, 17 Dec 2025 08
- Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick - Yahoo Finance hu, 08 Jan 2026 08
- Tenax Therapeutics (NASDAQ:TENX) Is In A Good Position To Deliver On Growth Plans - simplywall.st Sat, 10 Jan 2026 08
- Tenax Therapeutics (TENX): Analyst Raises Target Price to $25 | TENX Stock News - GuruFocus Wed, 17 Dec 2025 08
- Giordano buys Tenax Therapeutics (TENX) shares worth $19,999 - Investing.com hu, 20 Nov 2025 08
- We Think Tenax Therapeutics (NASDAQ:TENX) Can Afford To Drive Business Growth - Sahm Sat, 27 Sep 2025 07
- Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - Investing News Network Wed, 17 Dec 2025 08
- Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha Mon, 05 Jan 2026 08
- Responsive Playbooks and the TENX Inflection - Stock Traders Daily Sun, 08 Feb 2026 23
- Almenoff June Sherie, director at Tenax Therapeutics, buys $14944 in shares - Investing.com Wed, 19 Nov 2025 08
- TenX Protocols to Start Trading on TSX Venture Exchange After Raising $24M in 2025 - Yahoo Finance Wed, 10 Dec 2025 08
- Tenax Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network ue, 25 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 50000 | 625500 | — | Conversion of Exercise of derivative security at price 12.51 per share. | MCGAULEY THOMAS A | Chief Financial Officer | — | 2026-01-30 00:00:00 | D |
| 1 | 5000 | 50792 | — | Purchase at price 10.10 - 10.22 per share. | RICH STUART | Officer and Director | — | 2025-12-09 00:00:00 | D/I |
| 2 | 5000 | 45622 | — | Purchase at price 9.01 - 9.20 per share. | RICH STUART | Officer and Director | — | 2025-12-04 00:00:00 | D/I |
| 3 | 2605 | 20000 | — | Purchase at price 7.51 - 7.75 per share. | GIORDANO CHRISTOPHER THOMAS | Chief Executive Officer | — | 2025-11-20 00:00:00 | D |
| 4 | 1993 | 14945 | — | Purchase at price 7.15 - 7.52 per share. | ALMENOFF JUNE SHERIE | Director | — | 2025-11-18 00:00:00 | D |
| 5 | 1993 | 14945 | — | Purchase at price 7.15 - 7.52 per share. | ALMENOFF JUNE SHERIE | Director | — | 2025-11-18 00:00:00 | I |
| 6 | 8000 | 58164 | — | Purchase at price 7.23 - 7.35 per share. | MCGAULEY THOMAS A | Chief Financial Officer | — | 2025-11-17 00:00:00 | D/I |
| 7 | 1666 | 6781 | — | Purchase at price 4.07 per share. | PROEHL GERALD T | Director | — | 2024-08-08 00:00:00 | D |
| 8 | 2500 | 10175 | — | Purchase at price 4.07 per share. | DAVIDSON MICHAEL H | Director | — | 2024-08-08 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -17.58M | -7.68M | -10.93M | -32.36M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.60M | -7.71M | -11.05M | -32.47M |
| ReconciledDepreciation | 0.00 | 8.00K | 113.33K | 108.98K |
| EBITDA | -17.58M | -7.68M | -10.93M | -32.36M |
| EBIT | -17.58M | -7.69M | -11.04M | -32.47M |
| NetInterestIncome | 1.89M | 460.00K | -4.44K | -949.00 |
| InterestExpense | 23.00K | 24.00K | 4.44K | 949.00 |
| InterestIncome | 1.91M | 484.00K | ||
| NormalizedIncome | -17.60M | -7.71M | -11.05M | -32.47M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.60M | -7.71M | -11.05M | -32.47M |
| TotalExpenses | 19.49M | 8.23M | 11.05M | 32.73M |
| TotalOperatingIncomeAsReported | -19.49M | -8.23M | -11.05M | -32.73M |
| DilutedAverageShares | 15.27M | 248.45K | 18.39K | 12.86K |
| BasicAverageShares | 15.27M | 248.45K | 18.39K | 12.86K |
| DilutedEPS | -1.15 | -31.04 | -600.71 | -2.52K |
| BasicEPS | -1.15 | -31.04 | -600.71 | -2.52K |
| DilutedNIAvailtoComStockholders | -17.60M | -7.71M | -11.05M | -32.47M |
| NetIncomeCommonStockholders | -17.60M | -7.71M | -11.05M | -32.47M |
| NetIncome | -17.60M | -7.71M | -11.05M | -32.47M |
| NetIncomeIncludingNoncontrollingInterests | -17.60M | -7.71M | -11.05M | -32.47M |
| NetIncomeContinuousOperations | -17.60M | -7.71M | -11.05M | -32.47M |
| PretaxIncome | -17.60M | -7.71M | -11.05M | -32.47M |
| OtherIncomeExpense | 1.00K | 63.00K | 9.19K | 254.83K |
| OtherNonOperatingIncomeExpenses | 1.00K | 63.00K | 9.19K | 254.83K |
| NetNonOperatingInterestIncomeExpense | 1.89M | 460.00K | -4.44K | -949.00 |
| InterestExpenseNonOperating | 23.00K | 24.00K | 4.44K | 949.00 |
| InterestIncomeNonOperating | 1.91M | 484.00K | ||
| OperatingIncome | -19.49M | -8.23M | -11.05M | -32.73M |
| OperatingExpense | 19.49M | 8.23M | 11.05M | 32.73M |
| ResearchAndDevelopment | 12.71M | 3.23M | 5.38M | 25.15M |
| SellingGeneralAndAdministration | 6.79M | 5.00M | 5.68M | 7.58M |
| GeneralAndAdministrativeExpense | 6.79M | 5.00M | 5.68M | 7.58M |
| OtherGandA | 3.69M | 2.83M | 3.30M | 2.63M |
| SalariesAndWages | 3.10M | 2.18M | 2.37M | 4.95M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.42M | 298.28K | 28.65K | 15.75K |
| ShareIssued | 3.42M | 298.28K | 28.65K | 15.75K |
| TotalDebt | 501.00K | 807.89K | 290.78K | |
| TangibleBookValue | 91.99M | 8.10M | 1.49M | 4.24M |
| InvestedCapital | 91.99M | 8.60M | 2.12M | 4.24M |
| WorkingCapital | 91.99M | 8.10M | 1.36M | 4.13M |
| NetTangibleAssets | 91.99M | 8.10M | 1.49M | 4.24M |
| CapitalLeaseObligations | 0.00 | 183.59K | 290.78K | |
| CommonStockEquity | 91.99M | 8.10M | 1.49M | 4.24M |
| TotalCapitalization | 91.99M | 8.10M | 1.49M | 4.24M |
| TotalEquityGrossMinorityInterest | 91.99M | 8.10M | 1.49M | 4.24M |
| StockholdersEquity | 91.99M | 8.10M | 1.49M | 4.24M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | |||
| RetainedEarnings | -314.86M | -297.25M | -289.54M | -278.49M |
| AdditionalPaidInCapital | 406.85M | 305.35M | 291.03M | 282.74M |
| CapitalStock | 0.00 | 0.00 | 3.00 | 2.52K |
| CommonStock | 0.00 | 0.00 | 3.00 | 2.52K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.69M | 3.59M | 1.91M | 1.75M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 64.20K | 183.59K |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 64.20K | 183.59K | |
| LongTermCapitalLeaseObligation | 0.00 | 64.20K | 183.59K | |
| CurrentLiabilities | 4.69M | 3.59M | 1.85M | 1.56M |
| OtherCurrentLiabilities | 1.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 501.00K | 743.70K | 107.19K | |
| CurrentCapitalLeaseObligation | 0.00 | 119.39K | 107.19K | |
| CurrentDebt | 501.00K | 624.30K | ||
| OtherCurrentBorrowings | 624.30K | |||
| CurrentNotesPayable | 0.00 | 501.00K | 624.30K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.34M | 775.00K | 410.26K | 597.15K |
| PayablesAndAccruedExpenses | 3.36M | 2.31M | 693.82K | 859.64K |
| CurrentAccruedExpenses | 200.00K | 237.00K | 245.39K | 0.00 |
| Payables | 3.16M | 2.07M | 448.43K | 859.64K |
| AccountsPayable | 3.16M | 2.07M | 448.43K | 859.64K |
| TotalAssets | 96.69M | 11.69M | 3.40M | 5.99M |
| TotalNonCurrentAssets | 0.00 | 1.00K | 196.24K | 303.24K |
| OtherNonCurrentAssets | 1.00K | 9.55K | 8.44K | |
| NetPPE | 0.00 | 186.69K | 294.80K | |
| GrossPPE | 0.00 | 186.69K | 294.80K | |
| OtherProperties | 186.69K | 294.80K | ||
| CurrentAssets | 96.69M | 11.68M | 3.21M | 5.69M |
| OtherCurrentAssets | 64.00K | 252.00K | 345.86K | |
| PrepaidAssets | 1.77M | 1.64M | 738.93K | 105.08K |
| CashCashEquivalentsAndShortTermInvestments | 94.85M | 9.79M | 2.12M | 5.58M |
| OtherShortTermInvestments | 0.00 | |||
| CashAndCashEquivalents | 94.85M | 9.79M | 2.12M | 5.58M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.81M | -5.90M | -11.39M | -10.86M |
| RepaymentOfDebt | -501.00K | -624.00K | 0.00 | |
| IssuanceOfDebt | 624.30K | 0.00 | ||
| IssuanceOfCapitalStock | 9.19M | |||
| CapitalExpenditure | -2.32K | -5.25K | ||
| InterestPaidSupplementalData | 23.00K | 24.00K | ||
| EndCashPosition | 94.85M | 9.79M | 2.12M | 5.58M |
| BeginningCashPosition | 9.79M | 2.12M | 5.58M | 6.25M |
| ChangesInCash | 85.06M | 7.67M | -3.46M | -666.32K |
| FinancingCashFlow | 99.87M | 13.57M | 7.93M | 9.74M |
| CashFlowFromContinuingFinancingActivities | 99.87M | 13.57M | 7.93M | 9.74M |
| ProceedsFromStockOptionExercised | 100.37M | 14.19M | 7.93M | 9.74M |
| NetCommonStockIssuance | 9.19M | |||
| CommonStockIssuance | 9.19M | |||
| NetIssuancePaymentsOfDebt | -501.00K | -624.00K | 0.00 | 0.00 |
| NetShortTermDebtIssuance | -501.00K | -624.00K | 0.00 | 0.00 |
| ShortTermDebtPayments | -501.00K | -624.00K | 0.00 | |
| ShortTermDebtIssuance | 624.30K | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 0.00 | 3.00K | -2.32K | 452.61K |
| CashFlowFromContinuingInvestingActivities | 0.00 | 3.00K | -2.32K | 452.61K |
| NetInvestmentPurchaseAndSale | 0.00 | 457.86K | ||
| SaleOfInvestment | 0.00 | 803.40K | ||
| PurchaseOfInvestment | 0.00 | -345.54K | ||
| NetPPEPurchaseAndSale | 0.00 | 3.00K | -2.32K | -5.25K |
| SaleOfPPE | 0.00 | 3.00K | ||
| PurchaseOfPPE | -2.32K | -5.25K | ||
| OperatingCashFlow | -14.81M | -5.90M | -11.39M | -10.86M |
| CashFlowFromContinuingOperatingActivities | -14.81M | -5.90M | -11.39M | -10.86M |
| ChangeInWorkingCapital | 1.64M | 1.58M | -820.86K | -610.09K |
| ChangeInOtherCurrentLiabilities | 0.00 | -119.39K | -43.00K | |
| ChangeInPayablesAndAccruedExpense | 1.58M | 1.89M | -344.95K | -544.59K |
| ChangeInAccruedExpense | 523.00K | 237.00K | ||
| ChangeInPayable | 1.06M | 1.65M | ||
| ChangeInAccountPayable | 1.06M | 1.65M | ||
| ChangeInReceivables | 58.00K | -306.00K | -356.52K | -22.50K |
| ChangesInAccountReceivables | 58.00K | -306.00K | -356.52K | -22.50K |
| OtherNonCashItems | 23.00K | 24.00K | 4.44K | 21.58M |
| StockBasedCompensation | 1.12M | 191.00K | ||
| AmortizationOfSecurities | 0.00 | 9.43K | ||
| DepreciationAmortizationDepletion | 0.00 | 8.00K | 113.33K | 108.98K |
| DepreciationAndAmortization | 0.00 | 8.00K | 113.33K | 108.98K |
| Depreciation | 7.57K | 113.33K | 108.98K | |
| OperatingGainsLosses | 1.00K | 362.41K | 526.55K | |
| GainLossOnInvestmentSecurities | 190.85K | 365.31K | 773.79K | |
| GainLossOnSaleOfPPE | 0.00 | 1.00K | -2.90K | |
| NetIncomeFromContinuingOperations | -17.60M | -7.71M | -11.05M | -32.47M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TENX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|